Khan Najat sold $79K of RXRX

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

Recursion Pharmaceuticals (RXRX) stock rose 7.61% after positive AI-driven drug discovery results. The company reported Q2 2026 revenue of $7.7M, a net loss of $131M, and $545M in cash. It reduced its FY26 expense guidance to $375M, extending its cash runway into early 2028. Analysts have mixed views, with a consensus target of $7.22.

Analysts covering Recursion Pharmaceuticals (NASDAQ:RXRX) cut 2026 revenue forecasts by 19%, lowering consensus to about $53m, down 3.9% versus the prior 12 months. Loss per share is expected to improve slightly to about $0.88 versus $0.87 previously. The article also cites an expected annual revenue decline through 2026 versus prior growth.